loading...| Preferred Name |
Fingolimod Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7). |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C72782 |
|
| CAS_Registry |
162359-56-0 |
|
| CHEBI_ID |
CHEBI:63112 |
|
| Chemical_Formula |
C19H33NO2.HCl |
|
| code |
C72782 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively targets and binds to S1PR1 on lymphocytes and causes transient receptor activation followed by S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory M2 phenotype, and modulates their proliferation, morphology, and cytokine release via inhibition of the transient receptor potential cation channel, subfamily M, member 7 (TRPM7). |
|
| Display_Name |
Fingolimod Hydrochloride |
|
| FDA_UNII_Code |
G926EC510T |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 |
|
| label |
Fingolimod Hydrochloride |
|
| Legacy Concept Name |
Fingolimod_Hydrochloride |
|
| Preferred_Name |
Fingolimod Hydrochloride |
|
| prefixIRI |
NCIT:C72782 |
|
| prefLabel |
Fingolimod Hydrochloride |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0388087 |
|
| subClassOf |